Drug Database
IN

interferon alfa-2a (Proquiferon)

✓ Approved

Probiomed · IFNAR2 · 重组蛋白

什么是 interferon alfa-2a?

interferon alfa-2a 是一种重组蛋白,由Probiomed研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection、Subcutaneous Injection。

药物档案

商品名Proquiferon
公司Probiomed
药物类别重组蛋白
分子靶点IFNAR2
给药途径Injectable (Others), Intramuscular (IM) Injection, Subcutaneous Injection
状态Approved

作用机制

分子靶点

interferon alfa-2a 作用于 1 个分子靶点:

IFNAR2interferon alpha and beta receptor subunit 2 (IFNARB, IFN-alpha-REC)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

interferon alfa-2a 针对 8 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsAcquired immunodeficiency syndrome✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Hairy cell leukaemia✓ Approved
Infections and infestationsHepatitis B✓ Approved
Infections and infestationsHepatitis C✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Kaposi's sarcoma✓ Approved

注册免费账户还可查看另外 3 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedNature communications2026-11-19

Tumor-intrinsic PTPN12 suppresses anti-tumor immunity in colorectal cancer by restraining a dual epigenetic and cytoskeletal dsRNA sensing program.

Huo Yachang Y, Tian Yijun Y, Wang Dan D, Ping Yu Y et al.

Innate sensing of endogenous double-stranded RNA and the ensuing interferon response are crucial for the efficacy of immune checkpoint inhibition. Microsatellite stable colorectal cancer characteristically lacks this response, remaining immune-refractory with undefined intrinsic regulators. Here, through an in vivo clustered regularly interspaced short palindromic repeats screen, we identify PTPN12 as a physiological barrier that suppresses double-stranded RNA sensing and interferon response. TRIM28 was identified as a direct PTPN12 substrate here; PTPN12 removes phosphorylation at Y370 to stabilize repressive complexes and silence transposable elements, while concurrently rewiring the adhesive cytoskeleton to disrupt the spatially organization of cytosolic double-stranded RNA required for efficient innate sensing. Pharmacological inducible PTPN12 knockdown inhibits pre-established tumor growth and overcomes immunotherapy resistance in vivo, recapitulating PTPN12 ablation-induced massive double-stranded RNA accumulation. Our findings reveal a role for PTPN12 in coupling epigenetic silencing with cytoskeletal surveillance, suggesting potential strategies to augment anti-tumor immunity and overcome immunotherapy resistance in microsatellite stable colorectal cancer.

PMID 43052240
阅读全文 →
PubMedPulmonology2026-11-19

Nebulized interferon-β1a (SNG001) in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.

Qin Jinlv J, Wang Guizuo G, Han Dong D

This systematic review and meta-analysis aimed to determine the efficacy of nebulised interferon-β1a (SNG001) in patients with Coronavirus disease-2019 (COVID-19). A systematic search was conducted across PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Studies were searched up to November 2025. Randomised controlled trials (RCTs) on treatment of COVID-19 with SNG001, compared with placebo or standard of care, were reviewed. Data were analysed using the RevMan Version 5.1 (The Cochrane Collaboration). Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated for dichotomous outcomes. Four RCTs (enrolling 1055 participants) met the inclusion criteria. The proportion of patients with hospitalisations (data extracted from two RCTs) (RR 0.16, 95% CI 0.03 to 0.88), and serious adverse events (RR 0.65, 95% CI 0.47 to 0.90) were significantly fewer in SNG001 groups. There was no statistically significant difference in all-cause mortality (RR 0.72, 95% CI 0.37 to 1.39), patients non-recovery at day 28 (RR 0.87, 95% CI 0.65 to 1.17), and adverse event (RR 0.97, 95% CI 0.90 to 1.04) between the two groups. Nebulised SNG001 was safe and associated with a reduction in COVID-19-related hospital admission. SNG001 shows a potential benefit for outpatients with COVID-19, but it requires larger clinical trials for future validations, particularly in vaccinated and previously infected populations.

PMID 43053745
阅读全文 →
PubMedPhotochemistry and photobiology2026-11-19

Influence of ligand charge and pi-expansion on DNA binding ability of protic ruthenium complexes with light-activated anticancer activity.

Kuehner Elena C EC, Khweis Sarah A SA, Petersen Courtney M CM, Patel Ish I et al.

Photoactivated Ru(II) polypyridyl complexes containing diprotic ligands and extended π systems have been synthesized and investigated as anticancer agents in cell studies. The DNA binding properties of the photoactivated ruthenium complexes [(bphen)2Ru(4,4'-dhbp)]Cl2 (1A), [(dppz)2Ru(4,4'-dhbp)]Cl2 (2A), [(bphen)2Ru(4,7-dhphen)]Cl2 (3A), and [(dppz)2Ru(4,7-dhphen)]Cl2 (4A) were investigated to further characterize these compounds and their mode of action (where bphen = bathophenanthroline, dppz = dipyrido[3,2-a:2',3'-c]phenazine, 4,4'-dhbp = 4,4'-dihydroxy-2,2'-bipyridine, and 4,7-dhphen = 4,7-dihydroxy-1,10-phenanthroline). Initial studies probed the DNA binding ability of these compounds by circular dichroism and UV-Visible spectroscopy, and these methods were suggestive of DNA binding but not quantitative. DNA binding was further investigated by fluorescence emission quenching in a competitive binding assay, with each Ru complex displacing ethidium bromide. Ru compounds were evaluated relative to the weak DNA binder [Ru(bpy)3]Cl2 (Lit-1) and the known DNA intercalator [(phen)2Ru(dppz)]Cl2 (Lit-2). Stern-Volmer quenching constants and competitive binding constants were determined for each compound. Trends in binding affinity indicate the role of pH-sensitive ligand charge in binding DNA, providing further insight into the structure-activity relationship of these compounds.

PMID 43053657
阅读全文 →
PubMedMolecular neurodegeneration2026-11-19

Neurobiological correlates of longitudinal grey matter volume changes in preclinical Alzheimer's disease.

Pelkmans Wiesje W, Cacciaglia Raffaele R, Kassinopoulos Michalis M, Grau-Rivera Oriol O et al.

Structural brain changes during the earliest asymptomatic stages of Alzheimer's disease (AD) remain poorly understood. Previous research in preclinical AD shows heterogeneous findings, reporting both subtle neuronal loss and paradoxical increases in grey matter (GM) volume. This study applies an extensive cerebrospinal fluid (CSF) biomarker panel to better understand the biological processes underlying longitudinal GM changes in cognitively unimpaired (CU) adults, spanning the amyloid/tau (AT) continuum. We analysed data from 627 CU individuals from three longitudinal cohorts (ALFA+, Wisconsin ADRC, WRAP), with repeated MRI (3.5 ± 0.9 years) and baseline CSF biomarkers from the NeuroToolKit panel (Roche Diagnostics). Using non-negative matrix factorization, we decomposed the CSF biomarker levels into six latent components, reflecting amyloid-β (Aβ) pathology, tau-related pathophysiology with synaptic injury, neuroaxonal injury, microglial reactivity, astrocytic reactivity, and cytokine signalling. We tested associations between component weights and voxel-wise longitudinal GM volume changes using single-component and a joint-all components model. Analyses were performed across the full sample and stratified by AT status. Associations with longitudinal cognitive performance (PACC) were assessed using linear mixed-effects models. The Aβ pathology component was the strongest and most widespread predictor of longitudinal GM atrophy, predominantly in temporal and frontal regions, also when controlling for tau pathophysiology, neuroaxonal injury, or neuroinflammatory components. Higher Aβ pathology scores were also associated with cognitive decline. The component capturing tau-related pathophysiology and synaptic injury initially associated with GM loss but lost significance after accounting for other biomarker components. In contrast, components reflecting microglial reactivity, astrocytic reactivity, and cytokine signalling were associated with longitudinal GM volume increases, with effects varying by AT stage. In this large longitudinal sample of asymptomatic individuals, the Aβ-dominant biomarker component showed the strongest association with longitudinal GM atrophy and cognitive decline, beyond the effects of tau pathophysiology and neuroaxonal injury. While glial and inflammatory processes may contribute to transient GM increases in preclinical AD. A better understanding of these dynamic relationships between structural brain changes and various biological pathways at the earliest stages of AD is crucial to inform the development of interventions before irreversible neurodegeneration occurs.

PMID 43053204
阅读全文 →
PubMedCancer immunology, immunotherapy : CII2026-11-19

Tumor-associated antigen-reactive T cells and clinical outcomes in head and neck squamous cell carcinoma treated with pembrolizumab plus chemotherapy.

Sato Ryosuke R, Sakaue Shota S, Ominato Hisataka H, Inoue Takahiro T et al.

Blood-based biomarkers associated with clinical outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab plus chemotherapy remain poorly defined. We investigated 38 patients with HNSCC treated with pembrolizumab plus 5-fluorouracil and platinum (FP). Baseline systemic inflammation and immune status were assessed using routine laboratory parameters. Peripheral blood mononuclear cells were analyzed by flow cytometry to assess exhaustion- and activation-associated markers on CD4⁺ and CD8⁺ T cells, including CD38, Tim-3, PD-1, and ICOS. Tumor-associated antigen (TAA)-reactive immune responses were evaluated by interferon-γ production following stimulation with epidermal growth factor receptor (EGFR)- and c-Met-derived peptides. PD-L1 CPS positivity, elevated neutrophil-to-lymphocyte ratio, and higher frequencies of CD8⁺CD38⁺ T cells were associated with clinical outcomes, with similar trends observed for selected inflammatory and peripheral T-cell activation/exhaustion-associated markers. Tumor-associated antigen-reactive immune responses were detected in a subset of patients and were associated with prolonged progression-free survival, while EGFR peptide reactivity was additionally associated with improved overall survival. In this exploratory study, immune reactivity to TAAs was associated with favorable clinical outcomes in patients receiving pembrolizumab plus FP. Together with systemic inflammation and peripheral T-cell activation/exhaustion markers, these findings support further evaluation of integrated blood-based immune profiling, including TAA-reactive immune responses, as candidate biomarkers in larger prospective cohorts.

PMID 43052553
阅读全文 →
PubMedBMC medical genomics2026-11-19

Effect of SP110 single nucleotide polymorphisms on expression of selected cytokines in a Ugandan population with pulmonary tuberculosis.

Kyabaggu Denis S DS, Namuganga Anna Ritah AR, Muruhukye Jacob J, Katagirya Eric E et al.

The SP110 (speckled protein 110) is a nuclear body protein resulting from the expression of an interferon-stimulated gene crucial for macrophage-mediated killing of Mycobacterium tuberculosis (Mtb), the etiologic agent for human pulmonary tuberculosis (PTB). SP110 single nucleotide polymorphisms (SNPs) have been associated with susceptibility to PTB in different populations. However, the influence of SP110 genetic variants on quantitative host cytokine responses during active PTB remains poorly characterized, particularly in East African populations. We systematically evaluated the association between ten SP110 SNPs and plasma concentrations of six key immunoregulatory cytokines, IL-4, IL-6, IL-10, IFN-γ, TNF, and IFN-α, among bacteriologically confirmed PTB patients in Kampala, Uganda. We conducted a cross-sectional molecular epidemiological study among 153 adults with bacteriologically confirmed PTB recruited from Mulago National Referral Hospital and Kisenyi Health Centre IV, Kampala, Uganda. SP110 SNP genotyping was performed using a validated mass array protocol. Plasma cytokine concentrations were quantified by Luminex multiplex bead-based immunoassay and log₂-transformed before analysis. Genotype-phenotype associations were evaluated under additive, dominant, and recessive genetic inheritance models using multivariable generalized linear models adjusted for age, sex, HIV status, TB treatment status, and BCG vaccination scar. Multiple testing was controlled using the Benjamini-Hochberg false discovery rate (FDR) procedure. Multivariate immune profiling was conducted using Spearman correlation matrices and principal component analysis (PCA). Eight of the ten SP110 SNPs satisfied Hardy Weinberg Equilibrium (HWE), while rs11556887 and rs1427294 were near-monomorphic among the participants. All six cytokines were strongly intercorrelated (Spearman ρ = 0.38-0.85, all p < 0.001), and PCA demonstrated that a single dominant principal component, driven by IL-4, IFN-γ, TNF, IFN-α, and IL-10, explained 76.6% of inter-individual cytokine variance, reflecting a coordinated innate-adaptive immune response. One association survived Benjamini-Hochberg FDR correction: rs7580900 was significantly associated with IL-10 (β = - 2.02, 95% CI: - 3.03 to - 1.02, p < 0.001, FDR q = 0.019). Additional nominally significant associations (p < 0.05) were observed for rs2241525 and rs3948464 with IL-6 and IL-10 and for rs7580900 and rs3948464 with IFN-γ, though none of these secondary associations survived FDR correction. We report a significant association of SP110 rs7580900 with reduced IL-10 plasma concentrations among Ugandan PTB patients, implicating this variant in the modulation of anti-inflammatory regulatory responses during active Mtb infection. The strong cytokine co-expression profile observed across suggests a coordinated nature of the PTB immune response. The identified immune network structure supports the development of host-directed therapeutic strategies targeting cytokine regulation. Genetic screening of key regulatory variants such as SP110 rs7580900 may also contribute to innovative precision medicine approaches for tuberculosis management.

PMID 43053010
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多interferon alfa-2a